NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

僵直性脊椎炎市場調查報告:各藥物、各分子類型、各作用機制、各給藥途徑、各劑型、各終端用戶-至2025年的預測-COVID-19累積的影響

Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 990531
出版日期 內容資訊 英文 196 Pages
商品交期: 最快1-2個工作天內
價格
僵直性脊椎炎市場調查報告:各藥物、各分子類型、各作用機制、各給藥途徑、各劑型、各終端用戶-至2025年的預測-COVID-19累積的影響 Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 196 Pages
簡介

全球僵直性脊椎炎的市場規模,2020年為41億1,297萬美元/36億633萬歐元。該市場,預計達至2025年末為58億4,691萬美元/51億2,668萬歐元。

COVID-19是影響幾乎全部產業的無與倫比的世界公共衛生緊急事件,在預測期間內預計帶給產業的成長長期性的影響。目前進行的調查擴大了框架,以確保包括潛在的COVID-19問題和發展途徑。 本報告提供有關COVID-19的見解,其中考慮了消費者行為和需求的變化,購買方式,供應鏈的新路由,當前市場力量的動態以及政府的重要介入等COVID-19對市場的影響相關洞察。

本報告提供僵直性脊椎炎市場相關調查,市場概要,以及各藥物,各分子類型,各作用機制,各給藥途徑,各劑型,各終端用戶,各地區的趨勢,COVID-19累積的影響,及加入此市場的主要企業的簡介等。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和範圍
  • 調查對象年
  • 貨幣和價格
  • 語言
  • 限制事項
  • 利害關係者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 計劃:調查計劃作成
    • 實行:調查實施
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 簡介
  • 市場預測
  • 各劑型預測
  • 各給藥途徑預測
  • 各藥物預測
  • 各分子類型預測
  • 各作用機制預測
  • 各終端用戶預測
  • 各地區預測
  • 其他各競爭公司預測

第4章 市場概要

  • 簡介
  • COVID-19累積的影響
  • 地理性的成長機會

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特五力分析
    • 新加入業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 全球僵直性脊椎炎市場,各藥物

  • 簡介
  • Cimzia
  • Cosentyx
  • Enbrel
  • Humira
  • Remicade
  • Simponi

第7章 全球僵直性脊椎炎市場,各分子類型

  • 簡介
  • 生技藥品
  • 小分子

第8章 全球僵直性脊椎炎市場,各作用機制

  • 簡介
  • COX抑制劑
  • TNF抑制劑

第9章 全球僵直性脊椎炎市場,各給藥途徑

  • 簡介
  • 口服
  • 非口服

第10章 全球僵直性脊椎炎市場,各劑型

  • 簡介
  • 液體
  • 固體

第11章 全球僵直性脊椎炎市場,各終端用戶

  • 簡介
  • 診所
  • 醫院

第12章 南北美洲的僵直性脊椎炎市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章 亞太地區的僵直性脊椎炎市場

  • 簡介
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第14章 歐洲,中東、非洲的僵直性脊椎炎市場

  • 簡介
  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第15章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 協定,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第16章 企業的實用性簡介

  • Abbvie Inc.
  • Amgen Inc.
  • Biothera Pharmaceuticals, Inc.
  • Bristol-Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • Cadila Healthcare Limited
  • Celgene Corporation
  • Celltrion
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Hetero Drugs Limited
  • Izana Bioscience
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi SA
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Trinity Biotech Ireland
  • UCB Inc.
  • Xian Janssen Pharmaceutical Ltd

第17章 附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-A339DAEFAAAE

The Global Ankylosing Spondylitis Market size was estimated at USD 4,112.97 Million in 2020 and expected to reach USD 4,433.31 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.12% to reach USD 6,573.00 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Ankylosing Spondylitis to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug , the Ankylosing Spondylitis Market was studied across Cimzia, Cosentyx, Enbrel, Humira, Remicade, and Simponi.

Based on Type of Molecule, the Ankylosing Spondylitis Market was studied across Biologics and Small Molecules.

Based on Mechanism Of Action, the Ankylosing Spondylitis Market was studied across COX Inhibitors and TNF Inhibitors.

Based on Route Of Administration, the Ankylosing Spondylitis Market was studied across Oral and Parenteral.

Based on Dosage Forms, the Ankylosing Spondylitis Market was studied across Liquid and Solid.

Based on End User , the Ankylosing Spondylitis Market was studied across Clinics and Hospitals.

Based on Geography, the Ankylosing Spondylitis Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ankylosing Spondylitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ankylosing Spondylitis Market, including Abbvie Inc., Amgen Inc., Biothera Pharmaceuticals, Inc., Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Celgene Corporation, Celltrion, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Hetero Drugs Limited, Izana Bioscience, Johnson & Johnson Services, Inc., Merck & Co., Inc, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi SA, Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech Ireland, UCB Inc., and Xian Janssen Pharmaceutical Ltd.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Ankylosing Spondylitis Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ankylosing Spondylitis Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ankylosing Spondylitis Market?
  • 4. What is the competitive strategic window for opportunities in the Global Ankylosing Spondylitis Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Ankylosing Spondylitis Market?
  • 6. What is the market share of the leading vendors in the Global Ankylosing Spondylitis Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Ankylosing Spondylitis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Dosage Forms Outlook
  • 3.4. Route Of Administration Outlook
  • 3.5. Drug Outlook
  • 3.6. Type of Molecule Outlook
  • 3.7. Mechanism Of Action Outlook
  • 3.8. End User Outlook
  • 3.9. Geography Outlook
  • 3.10. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of ankylosing spondylitis
      • 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
    • 5.1.2. Restraints
      • 5.1.2.1. Expiry patent of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in research and development expenditure for the treatment of the spondylitis
      • 5.1.3.2. Introduction of the biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of treatment and limited of skilled surgeons and physiotherapists
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Ankylosing Spondylitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Cimzia
  • 6.3. Cosentyx
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. COX Inhibitors
  • 8.3. TNF Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms

  • 10.1. Introduction
  • 10.2. Liquid
  • 10.3. Solid

11. Ankylosing Spondylitis Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Hospitals

12. Americas Ankylosing Spondylitis Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States
    • 12.6.1. California
    • 12.6.2. Florida
    • 12.6.3. Illinois
    • 12.6.4. New York
    • 12.6.5. Ohio
    • 12.6.6. Pennsylvania
    • 12.6.7. Texas

13. Asia-Pacific Ankylosing Spondylitis Market

  • 13.1. Introduction
  • 13.2. China
  • 13.3. India
  • 13.4. Indonesia
  • 13.5. Japan
  • 13.6. Malaysia
  • 13.7. Philippines
  • 13.8. South Korea
  • 13.9. Thailand

14. Europe, Middle East & Africa Ankylosing Spondylitis Market

  • 14.1. Introduction
  • 14.2. France
  • 14.3. Germany
  • 14.4. Italy
  • 14.5. Netherlands
  • 14.6. Qatar
  • 14.7. Russia
  • 14.8. Saudi Arabia
  • 14.9. South Africa
  • 14.10. Spain
  • 14.11. United Arab Emirates
  • 14.12. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
    • 15.1.1. Quadrants
    • 15.1.2. Business Strategy
    • 15.1.3. Product Satisfaction
  • 15.2. Market Ranking Analysis
  • 15.3. Market Share Analysis, By Quadrant
  • 15.4. Market Share Analysis, By Company
  • 15.5. Competitive Scenario
    • 15.5.1. Merger & Acquisition
    • 15.5.2. Agreement, Collaboration, & Partnership
    • 15.5.3. New Product Launch & Enhancement
    • 15.5.4. Investment & Funding
    • 15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles

  • 16.1. Abbvie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Biothera Pharmaceuticals, Inc.
  • 16.4. Bristol-Myers Squibb
  • 16.5. C.H. Boehringer Sohn AG & Ko. KG
  • 16.6. Cadila Healthcare Limited
  • 16.7. Celgene Corporation
  • 16.8. Celltrion
  • 16.9. Eisai Co., Ltd
  • 16.10. Eli Lilly and Company
  • 16.11. F. Hoffmann-La Roche AG
  • 16.12. Hetero Drugs Limited
  • 16.13. Izana Bioscience
  • 16.14. Johnson & Johnson Services, Inc.
  • 16.15. Merck & Co., Inc
  • 16.16. Novartis AG
  • 16.17. Pfizer Inc.
  • 16.18. Regeneron Pharmaceuticals, Inc
  • 16.19. Reliance Life Sciences
  • 16.20. Samsung Bioepis Co., Ltd.
  • 16.21. Sandoz International GmbH
  • 16.22. Sanofi SA
  • 16.23. Shanghai Pharmaceuticals Holding Co., Ltd.
  • 16.24. Trinity Biotech Ireland
  • 16.25. UCB Inc.
  • 16.26. Xian Janssen Pharmaceutical Ltd

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing
  • 17.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 (USD MILLION)
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MARKET DYNAMICS
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2026 (%)
  • FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2026 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2026
  • FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2026 (%)
  • FIGURE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2026
  • FIGURE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (%)
  • FIGURE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2026
  • FIGURE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
  • FIGURE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD MILLION)
  • FIGURE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (%)
  • FIGURE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (USD MILLION)
  • FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2026
  • FIGURE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, 2018-2026 (USD MILLION)
  • FIGURE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, 2018-2026 (USD MILLION)
  • FIGURE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2026 (%)
  • FIGURE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2026 (USD MILLION)
  • FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2026
  • FIGURE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, 2018-2026 (USD MILLION)
  • FIGURE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
  • FIGURE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 62. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 64. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 77. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 78. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 79. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 80. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 81. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 82. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 84. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 85. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 86. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 87. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 88. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 89. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 90. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 91. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 92. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 93. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 94. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 95. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 96. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 97. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 98. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 99. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 100. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 101. GLOBAL ANKYLOSING SPONDYLITIS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 102. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 103. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 104. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANKYLOSING SPONDYLITIS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. CALIFORNIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. FLORIDA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. ILLINOIS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. NEW YORK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. OHIO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. PENNSYLVANIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. TEXAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 126. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 127. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 128. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 129. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 130. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 131. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 132. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 133. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 134. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 135. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 136. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 137. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 138. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 139. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 140. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 141. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 142. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 143. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 144. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 145. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 146. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 147. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 148. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 149. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 150. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 151. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 152. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 153. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 154. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 155. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 156. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 157. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 158. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 159. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 167. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 168. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 169. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 170. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 173. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 174. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 175. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 176. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 179. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 180. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 181. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 182. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 183. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 184. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 185. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 186. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 187. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 188. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 189. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 190. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 191. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 192. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 193. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 194. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 195. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 196. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 197. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 198. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 199. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 200. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 201. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 202. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 203. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 204. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 205. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 206. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 207. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 208. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 209. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 210. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 211. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 212. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 213. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 214. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 215. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 216. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 217. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 218. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 219. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 220. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 227. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 228. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 229. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 230. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 231. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 232. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 233. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SCORES
  • TABLE 234. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BUSINESS STRATEGY
  • TABLE 235. GLOBAL ANKYLOSING SPONDYLITIS MARKET: PRODUCT SATISFACTION
  • TABLE 236. GLOBAL ANKYLOSING SPONDYLITIS MARKET: RANKING
  • TABLE 237. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 238. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 239. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MERGER & ACQUISITION
  • TABLE 240. GLOBAL ANKYLOSING SPONDYLITIS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 241. GLOBAL ANKYLOSING SPONDYLITIS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 242. GLOBAL ANKYLOSING SPONDYLITIS MARKET: INVESTMENT & FUNDING
  • TABLE 243. GLOBAL ANKYLOSING SPONDYLITIS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 244. GLOBAL ANKYLOSING SPONDYLITIS MARKET: LICENSE & PRICING
  • TABLE 245. GLOBAL ANKYLOSING SPONDYLITIS MARKET: CONTACT DETAILS